# SPINRAZA (nusinersen) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/nusinersen

> SPINRAZA (nusinersen), sponsored by BIOGEN INC. (BIIB), received a complete response letter from the FDA; the decision is dated September 22, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | SPINRAZA (nusinersen) |
| Codes | BIIB058 |
| Sponsor | BIOGEN INC. (BIIB) https://sec-api.dev/companies/biib/catalysts |
| Indications | [Muscular Atrophy, Spinal](https://sec-api.dev/indications/muscular-atrophy-spinal), [Spinal Muscular Atrophy](https://sec-api.dev/indications/spinal-muscular-atrophy) |
| Modality | antisense |
| FDA designations | priority review |

## Timeline

### December 23, 2016: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209531 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20161223, review_priority PRIORITY; sponsor_name BIOGEN; product SPINRAZA (NUSINERSEN SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209531%22

### June 16, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209531 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20200616, review_priority STANDARD; sponsor_name BIOGEN; product SPINRAZA (NUSINERSEN SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209531%22

### Sep 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2/3.
- First seen 2025-02-12, last confirmed 2025-02-12.
- SEC Form 10-K (accession 0000875045-25-000009): "•In September 2024 we announced positive topline data from the Phase 2/3 DEVOTE study of nusinersen, which evaluated the safety and efficacy of a higher dose regimen of nusinersen in treatment-naive symptomatic infants with SMA." https://www.sec.gov/Archives/edgar/data/875045/000087504525000009/biib-20241231.htm
- SEC Form 10-K (accession 0000875045-25-000009): "In September 2024 we announced positive topline data from the Phase 2/3 DEVOTE study of nusinersen, which evaluated the safety and efficacy of a higher dose regimen of nusinersen in treatment-naive symptomatic infants with SMA." https://www.sec.gov/Archives/edgar/data/875045/000087504525000009/biib-20241231.htm

### September 22, 2025: PDUFA date

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-02-12, last confirmed 2025-07-30.
- Press release filed with the SEC (EX-99) (accession 0000875045-25-000004): "•Nusinersen (SPINRAZA) higher dose regimen for SMA filings accepted by FDA and EMA; FDA PDUFA of September 22, 2025" https://www.sec.gov/Archives/edgar/data/875045/000087504525000004/exhibit991-q42024pressrele.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-027949): "Higher dose nusinersen under review for marketing approval in the U.S. (PDUFA date of September 22, 2025) and in the EU" https://www.sec.gov/Archives/edgar/data/874015/000114036125027949/ef20052929_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-016562): "Higher dose nusinersen under review for marketing approval in U.S. (PDUFA date of September 22, 2025) and EU" https://www.sec.gov/Archives/edgar/data/874015/000114036125016562/ef20048172_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-005080): "Higher dose nusinersen under regulatory review in U.S. (PDUFA date of September 22, 2025) and EU" https://www.sec.gov/Archives/edgar/data/874015/000114036125005080/ef20043828_ex99-1.htm
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA209531_20250922.pdf%22

### September 22, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA209531_20250922.pdf%22

### March 27, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209531 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20260327, review_priority STANDARD; sponsor_name BIOGEN; product SPINRAZA (NUSINERSEN SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209531%22

### April 3, 2026: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2025-10-30, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0000875045-25-000047): "•Today announced that high dose nusinersen (SPINRAZA) in SMA was successfully resubmitted with the FDA with an updated PDUFA date of April 3, 2026" https://www.sec.gov/Archives/edgar/data/875045/000087504525000047/exhibit991-q32025pressrele.htm
- SEC Form 10-K (accession 0000875045-26-000013): "We resubmitted the supplemental NDA to the FDA, which has been accepted for review with a PDUFA action date of April 3, 2026." https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm
- SEC Form 10-K (accession 0000874015-26-000115): "Higher dose SPINRAZA was approved in EU and Japan in 2025 and is currently under review in the U.S. with a PDUFA action date of April 3, 2026." https://www.sec.gov/Archives/edgar/data/874015/000087401526000115/form10k.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-006718): "High dose approved and launched in the EU; under review for marketing approval in U.S. (PDUFA date of April 3, 2026)" https://www.sec.gov/Archives/edgar/data/874015/000114036126006718/ef20066495_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0000875045-26-000011): "•High dose regimen of SPINRAZA approved in Japan and E.U.; U.S. FDA PDUFA of April 3, 2026" https://www.sec.gov/Archives/edgar/data/875045/000087504526000011/exhibit991-q42025pressrele.htm
- openFDA Drugs@FDA: "NDA209531 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20260327, review_priority STANDARD; sponsor_name BIOGEN; product SPINRAZA (NUSINERSEN SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209531%22

### July 30, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Muscular Atrophy, Spinal.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04729907 (A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-30 (ACTUAL); Lead Sponsor Biogen." https://clinicaltrials.gov/study/NCT04729907

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Spinal Muscular Atrophy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05067790 (A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Biogen." https://clinicaltrials.gov/study/NCT05067790

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Spinal Muscular Atrophy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05067790 (A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Biogen." https://clinicaltrials.gov/study/NCT05067790

## Same indication

- [ISEMBYLD (apitegromab)](https://sec-api.dev/pdufa/apitegromab) (SRRK)
- [Salanersen](https://sec-api.dev/pdufa/salanersen) (BIIB)

Calendar months: [September 2027](https://sec-api.dev/fda-calendar/2027-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/nusinersen.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SPINRAZA (nusinersen) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/nusinersen

```bibtex
@misc{secapidev_pdufa_nusinersen_20261116,
  title        = {SPINRAZA (nusinersen) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/nusinersen}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_nusinersen_20261116","title":"SPINRAZA (nusinersen) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/nusinersen","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
